InflaRx is a clinical-stage biopharmaceutical company focused on applying its anti-C5a technology to discover and develop specific inhibitors of the complement activation factor known as C5a. C5a is an inflammatory mediator involved in the progression of a variety of autoimmune and other inflammatory diseases. Co.'s primary product candidate, vilobelimab, is an intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in various clinical settings. Co. develops vilobelimab for the treatment of Hidradenitis Suppurativa, a rare and chronic debilitating systemic inflammatory skin disease. The IFRX stock yearly return is shown above.
The yearly return on the IFRX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the IFRX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|